Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CerusCERS +0.55%78 Days Payable is 106.76 as of Jun. 2026, which is 34% below its 10-year median of 162.75. GuruFocus rates CERS with a GF Score™ of 78/100 and a GF Value™ of $2.23 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 793 Medical Devices & Instruments companies, Cerus ranks better than 66.96% on this metric.
Cerus's average Accounts Payable for the
three
months ended in Jun. 2026 was $32.7 Mil. Cerus's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $27.9 Mil.
Hence, Cerus's Days Payable for the
three
months ended in Jun. 2026 was 106.76.
The historical rank and industry rank for Cerus's Days Payable or its related term are showing as below:
CERS'
s Days Payable Range Over the Past 10 Years
Min: 96.66 Med: 162.75 Max: 222.7
Current: 102.59
During the past 13 years, Cerus's highest Days Payable was 222.70. The lowest was 96.66. And the median was 162.75.
CERS's Days Payable is ranked better than 66.96% of 793
companies
in the Medical Devices & Instruments industry
Industry Median: 68.47
vs CERS: 102.59
Cerus's Days Payable
declined
from Jun. 2025 (113.13) to Jun. 2026 (106.76).
It may suggest that Cerusaccelerated paying its suppliers.
The historical data trend for Cerus's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Cerus's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cerus Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Days Payable distribution charts can be found below:
* The bar in red indicates where Cerus's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cerus's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cerus (CERS) has a Days Payable of 106.76 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cerus and its competitors. This is 34% below median its historical median of 162.75. Over the past decade, Cerus' Days Payable has ranged from 96.66 to 222.70. According to the industry distribution chart, Cerus ranks #262 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 33%.
Is Cerus' Days Payable too high?
Cerus' current Days Payable of 106.76 is 34% below median its 10-year median of 162.75. Over the past 10 years, this metric has ranged from a low of 96.66 to a high of 222.70. The Medical Devices & Instruments industry median Days Payable is 68.47. Cerus' value of 106.76 is 55.9% above this industry median. Based on the distribution chart, Cerus ranks #262 out of 793 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Cerus has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cerus' Days Payable compare to CTKB and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cerus ranks #262 out of 793 companies for Days Payable. This puts Cerus in the upper half of its industry. The industry median Days Payable is 68.47. Cerus' value of 106.76 is 55.9% above this benchmark. Historically, Cerus' own Days Payable has ranged from 96.66 to 222.70 over the past decade. While the company's 10-year median is 162.75 vs. the industry median of 68.47, Cerus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.47, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cerus's current Days Payable of 106.76 is 55.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cerus and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cerus's current Days Payable is 106.76, which is 34% below median its own 10-year median of 162.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (CERS) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.23, compared to a current price of $2.74 — trading 22.9% above its estimated fair value. The current Days Payable is 106.76, which is 34% below median its 10-year median of 162.75 and 55.9% above the Medical Devices & Instruments industry median of 68.47. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cerus (CERS), the current Days Payable is 106.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cerus (CERS) Overvalued in 2026?
Based on GuruFocus' analysis, Cerus stock appears to be overvalued.
The current stock price of $2.74 is trading 22.9% above its estimated GF Value™ of $2.23.
GuruFocus considers Cerus to be Modestly Overvalued.
Key valuation signals for CERS:
Days Payable: 106.76 (34% below median its 10-year median of 162.75)
GF Value™: $2.23 vs. price of $2.74 (22.9% above fair value)
Industry Position: 55.9% above the Medical Devices & Instruments median (#262 of 793)
No single metric tells the full story. See the CERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score
Get the complete analysis for CERS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERS has been successfully added to your 
